ReviewFrontiers in pharmacology2025
Application of artificial intelligence large language models in drug target discovery.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- DataXflowGen for GenAI-driven model generation.Scientific reports · 2026Article
- A progressive fine-tuning strategy for domain-specific large language models in wastewater treatment plants safety.Scientific reports · 2026Article
- Crosstalk between autophagy and ferroptosis in liver diseases (Review).International journal of molecular medicine · 2026Review
- Protein and ligand novelty in drug-target interaction prediction: a dual-encoder fusion strategy for more interpretable and generalizable modeling.BMC bioinformatics · 2026Article
- Computational proteomics to enhance personalized treatment of COVID-19 and Long COVID.Clinical proteomics · 2026Review
- Beyond the hype: navigating the real-world applications of artificial intelligence (AI) in healthcare.Medical review (2021) · 2026Review
- Molecular life sciences in the era of the Fourth Industrial Revolution: sequencing, multi-omics and artificial intelligence.Emerging topics in life sciences · 2025Review
- AI reshaping life sciences: intelligent transformation, application challenges, and future convergence in neuroscience, biology, and medicine.Frontiers in digital health · 2025Review
- Advances in artificial intelligence applications for the management of chronic obstructive pulmonary disease.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug target discovery is a fundamental aspect of contemporary drug research and development. However, the use of conventional biochemical screening, omics analysis, and related approaches is constrained by substantial technical complexity and significant resource requirements. With the advancement of artificial intelligence-based large language models, notable progress has been achieved in drug target identification. During target mining, large language models with natural language comprehension capabilities can efficiently integrate literature data resources and systematically analyze disease-associated biological pathways and potential targets. Notably, models specifically designed for biomolecular "language" have demonstrated advantages across multiple aspects. The genomics-focused large language model has significantly enhanced the accuracy of pathogenic gene variant identification and gene expression prediction. In transcriptomics, large language models enable comprehensive reconstruction of gene regulatory networks. In proteomics, advancements have been made in protein structure analysis, function prediction, and interaction inference. Additionally, the single-cell multi-omics large language model facilitates data integration across different omics technologies. These technological advancements provide multi-dimensional biological evidence supporting drug target discovery and contribute to a more efficient screening process for candidate targets. The development of these models is generally based on deep neural networks of Transformer architecture, and powerful representation capabilities are obtained through large-scale unsupervised pre-training (such as mask language modeling, autoregressive prediction) combined with task-specific supervised fine-tuning. This review systematically examines recent advancements in the application of large language models in drug target discovery, emphasizing existing technical challenges and potential future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.